New psoriasis pill shows promise in early trial

NCT ID NCT05730725

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could significantly reduce psoriasis skin symptoms (measured by PASI-75) and to check for side effects. The study is already completed, and results will help decide if larger trials are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986322
What this could lead to: If successful, this could lead to a new oral treatment option for people with moderate-to-severe psoriasis.
What could go wrong: This is an early-phase trial with only 109 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Los Angeles, California, 90045-3606, United States
Local Institution - 0002

Fremont, California, 94538, United States
Local Institution - 0003

Santa Ana, California, 92701-2201, United States
Local Institution - 0004

Beverly, Massachusetts, 01915-1672, United States
Local Institution - 0005

Fountain Valley, California, 92708-3701, United States
Local Institution - 0006

Birmingham, Alabama, 35205-5021, United States
Local Institution - 0007

Portsmouth, New Hampshire, 03801, United States
Local Institution - 0008

Cleveland, Ohio, 44106-1716, United States
Local Institution - 0011

Webster, Texas, 77598, United States
Local Institution - 0012

Encino, California, 91436, United States
Local Institution - 0013

Coral Gables, Florida, 33134-5736, United States
Local Institution - 0016

Los Angeles, California, 90056, United States
Local Institution - 0019

Carlton, Victoria, 3053, Australia
Local Institution - 0020

Hamilton, Ontario, L8L 3C3, Canada
Local Institution - 0023

tabashi City, Tokyo, 1738606, Japan
Local Institution - 0024

Brisbane, Queensland, 4102, Australia
Local Institution - 0026

Nagoya, 467-8602, Japan
Local Institution - 0027

Tsu, 514-8507, Japan
Local Institution - 0030

Toronto, Ontario, M2N 3A6, Canada
Local Institution - 0034

Barrie, Ontario, L4M 7G1, Canada
Local Institution - 0041

London, Ontario, N6A 2C2, Canada
Local Institution - 0042

Itabashi-Ku, 173-8610, Japan
Local Institution - 0044

Clarksville, Indiana, 47129-2201, United States
Local Institution - 0045

Pascoe Vale South, Victoria, 3044, Australia
Local Institution - 0046

Leytonstone, E11 1NR, United Kingdom
Local Institution - 0049

Sapporo, Hokkaido, 064-0807, Japan
Local Institution - 0050

Hinckley, LEC, LE10 2SE, United Kingdom
Local Institution - 0051

Fukuoka, 814-0180, Japan
Local Institution - 0055

Durham, North Carolina, 27713-8507, United States
Local Institution - 0056

Skokie, Illinois, 60077-1049, United States
Local Institution - 0057

Leawood, Kansas, 66211, United States
Local Institution - 0058

Rapid City, South Dakota, 57702-9208, United States
Local Institution - 0059

Dallas, Texas, 75230-5808, United States
Local Institution - 0060

Lee's Summit, Missouri, 64064, United States
Local Institution - 0062

St. John's, Newfoundland and Labrador, A1E 1V4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.